ALUR Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -447.1% compared to Allurion Technologies, Inc.'s net margin of -12425.36%. Allurion Technologies, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Allurion Technologies, Inc. has a consensus price target of $5.25, signalling upside risk potential of 277.7%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Perspective Therapeutics, Inc. has higher upside potential than Allurion Technologies, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Allurion Technologies, Inc..

Allurion Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Allurion Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Allurion Technologies, Inc. quarterly revenues are $2.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Allurion Technologies, Inc.'s net income of -$11.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Allurion Technologies, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies, Inc. is 0.47x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of -447.1% compared to Allurion Technologies, Inc.'s net margin of 12.4%. Allurion Technologies, Inc.'s return on equity of -- beat Insulet Corp.'s return on equity of 18.92%.

Allurion Technologies, Inc. has a consensus price target of $5.25, signalling upside risk potential of 277.7%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 30.78%. Given that Allurion Technologies, Inc. has higher upside potential than Insulet Corp., analysts believe Allurion Technologies, Inc. is more attractive than Insulet Corp..

Allurion Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Allurion Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Allurion Technologies, Inc. quarterly revenues are $2.7M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Allurion Technologies, Inc.'s net income of -$11.9M is lower than Insulet Corp.'s net income of $87.6M. Notably, Allurion Technologies, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 83.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies, Inc. is 0.47x versus 8.29x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -447.1% compared to Allurion Technologies, Inc.'s net margin of -862.39%. Allurion Technologies, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.

Allurion Technologies, Inc. has a consensus price target of $5.25, signalling upside risk potential of 277.7%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than Allurion Technologies, Inc., analysts believe VolitionRX Ltd. is more attractive than Allurion Technologies, Inc..

Allurion Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Allurion Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Allurion Technologies, Inc. quarterly revenues are $2.7M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Allurion Technologies, Inc.'s net income of -$11.9M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Allurion Technologies, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies, Inc. is 0.47x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -447.1% compared to Allurion Technologies, Inc.'s net margin of 3.93%. Allurion Technologies, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Allurion Technologies, Inc. has a consensus price target of $5.25, signalling upside risk potential of 277.7%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Allurion Technologies, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Allurion Technologies, Inc. is more attractive than Xtant Medical Holdings, Inc..

Allurion Technologies, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Allurion Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Allurion Technologies, Inc. quarterly revenues are $2.7M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Allurion Technologies, Inc.'s net income of -$11.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Allurion Technologies, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies, Inc. is 0.47x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.